Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
BOTHELL, Wash., May 07, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Paul B. Cleveland, Interim President and Chief Executive Officer, at the 2018 Bank of America Merrill Lynch Health Care Conference at 1:15 p.m. PT on Tuesday, May 15, 2018 in Las Vegas, NV.
A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after the live event concludes.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contacts:
Ashwin Agarwal
Vice President, Corporate Strategy
Alder Biopharmaceuticals, Inc.
425-408-8567
[email protected]
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Andy Brimmer / Aura Reinhard / Trevor Gibbons
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
